Atlanta 9/6/2013 3:00:00 AM
News / Finance

Advaxis (ADXS) Publishes Preclinical Research for HPV Treatment Candidate

MissionIR would like to highlight Advaxis (OTCBB:ADXS), a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

In the company’s news,

Advaxis announced that it has published the preclinical research for ADXS-HPV, Advaxis’ Lm-LLO lead drug candidate. The product is designed for use in the treatment of HPV-associated cancers in combination with the PD-1 antibody.

The paper, titled “Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy,” has been e-published in the Journal for Immunotherapy of Cancer. Dr. Samir N. Khleif and his research team conducted the research at the Georgia Regents University Cancer Center. Advaxis provided the Lm-LLO immunotherapies and partial research funding.

Among the studies’ various findings, it was demonstrated that treatment with an Lm-LLO immunotherapy, in combination with an anti-PD-1 antibody, significantly improved immune and therapeutic efficacy in preclinical mouse models.

The study also showed that a significant reduction of regulatory T cells and myeloid-derived suppressor cells in spleen and tumor microenvironments were mediated solely by the Lm-LLO immunotherapy. The addition of anti-PD-1 antibody to the Lm-LLO immunotherapy treatment resulted in an increase in antigen-specific immune responses in the periphery and in CD8 T cell infiltration into the tumor. As a result, this treatment combination led to inhibition of tumor growth and prolonged survival, while also completing regression of tumors, in treated animals.

Based on the findings in the mouse model, the team conducted additional studies to evaluate activity in human cells. Lm-LLO immunotherapy treatment was found to significantly upregulate surface PD-L1 expression on human monocyte-derived dendritic cells isolated. This finding suggests that the combination of Lm-LLO immunotherapy with an anti-PD-1 antibody could have clinical application.

“Previous studies with Lm-LLO immunotherapies have established the ability to combine with chemotherapy and radiation. Dr. Khleif’s data are first to show the potential of combining Advaxis constructs with promising immune modulator (PD-1) in active clinical development,” commented Dr. Petit, Chief Scientific Officer of Advaxis.  

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit

To connect with MissionIR via Facebook, please visit

To connect with MissionIR via Twitter, please visit

Please read FULL disclaimer on the MissionIR website:

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.